← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Zentek Ltd. (ZTEK) 10-Year Financial Performance & Capital Metrics

ZTEK • • Industrial / General
HealthcareMedical InstrumentsMedical Consumables & DisposablesSafety Syringes & Injectables
AboutZentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.Show more
  • Revenue $872K +2826.3%
  • EBITDA -$9M +20.8%
  • Net Income -$10M +14.2%
  • EPS (Diluted) -0.10 +16.7%
  • Gross Margin 22.06% +102.2%
  • EBITDA Margin -1031.56% +97.3%
  • Operating Margin -1100.37% +97.3%
  • Net Margin -1150.68% +97.1%
  • ROE -67.74% -31.0%
  • ROIC -46.86% +3.3%
  • Debt/Equity 0.05 -25.1%
  • Interest Coverage -105.13 +5.8%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y36.95%
TTM2225.73%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM23.7%

EPS CAGR

10Y-
5Y-
3Y-
TTM27.98%

ROCE

10Y Avg-27.27%
5Y Avg-43.44%
3Y Avg-53.48%
Latest-63.49%

Peer Comparison

Safety Syringes & Injectables
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
UTMDUtah Medical Products, Inc.188.76M58.9214.88-18.56%32.33%10.68%7.73%0.00
STSSSharps Technology, Inc.63.21M2.18-0.00-324.78%-4.98%1.89
RVPRetractable Technologies, Inc.21.55M0.72-1.80-24.19%-22.9%-11.43%0.01
XRAYDENTSPLY SIRONA Inc.2.46B12.35-2.76-4.34%-24.34%-59.68%11.4%1.17
ZTEKZentek Ltd.96.58M0.90-928.26%-8.95%-70.13%0.05

Profit & Loss

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales/Revenue+000002.35K339.67K72.86K29.82K872.5K
Revenue Growth %------143.23%-0.79%-0.59%28.26%
Cost of Goods Sold+11.38K9.71K6.07K5.3K17.48K196.03K376.79K853.34K331.08K680.01K
COGS % of Revenue-----83.24%1.11%11.71%11.1%0.78%
Gross Profit+-11.38K-9.71K-6.07K-5.3K-17.48K-193.67K-37.12K-780.48K-301.26K192.49K
Gross Margin %------82.24%-0.11%-10.71%-10.1%0.22%
Gross Profit Growth %-0.15%0.38%0.13%-2.3%-10.08%0.81%-20.03%0.61%1.64%
Operating Expenses+4.2M2.85M1.64M2.47M1.16M4.12M12.53M13.87M11.68M9.79M
OpEx % of Revenue-----1749.49%36.88%190.41%391.64%11.22%
Selling, General & Admin4.19M2.84M1.63M2.46M1.16M3.53M9.56M10.99M8.95M8.01M
SG&A % of Revenue-----1498.28%28.16%150.88%300.01%9.18%
Research & Development0000001.54M1.65M1.78M465.65K
R&D % of Revenue------4.54%22.59%59.55%0.53%
Other Operating Expenses11.38K9.71K6.07K23.89K0591.6K1.42M1.23M956.7K1.31M
Operating Income+-4.2M-2.85M-1.64M-2.47M-1.18M-4.31M-12.56M-14.65M-11.98M-9.6M
Operating Margin %------1831.73%-36.99%-201.12%-401.75%-11%
Operating Income Growth %-0.37%0.32%0.42%-0.51%0.52%-2.66%-1.91%-0.17%0.18%0.2%
EBITDA+-4.19M-2.84M-1.63M-2.46M-1.16M-4.23M-11.95M-14.11M-11.36M-9M
EBITDA Margin %------1797.03%-35.18%-193.72%-381.16%-10.32%
EBITDA Growth %-0.38%0.32%0.42%-0.51%0.53%-2.64%-1.82%-0.18%0.19%0.21%
D&A (Non-Cash Add-back)11.38K9.71K6.07K5.3K17.48K81.72K614.71K539.69K613.71K600.32K
EBIT-4.16M-2.82M-1.6M-2.38M-1.08M-4.09M-31.63M-14.29M-11.7M-9.95M
Net Interest Income+00004.59K-6.93K-43.18K389.63K298.11K10.29K
Interest Income4.07K5.53K75.31K16.41K6.53K3.27K20.6K510.26K405.48K101.61K
Interest Expense0000010.19K63.78K120.62K107.37K91.32K
Other Income/Expense4.07K5.53K75.31K40.3K96.25K445.07K-19.13M238.68K174.74K-439.03K
Pretax Income+-4.2M-2.84M-1.56M-2.43M-1.08M-3.87M-31.69M-14.41M-11.8M-10.04M
Pretax Margin %------1642.74%-93.31%-197.85%-395.89%-11.51%
Income Tax+00000000-99.78K0
Effective Tax Rate %1%1%1%1%1%1%1%1%0.99%1%
Net Income+-4.2M-2.84M-1.56M-2.43M-1.08M-3.87M-31.69M-14.41M-11.7M-10.04M
Net Margin %------1642.74%-93.31%-197.85%-392.54%-11.51%
Net Income Growth %-0.39%0.32%0.45%-0.55%0.55%-2.57%-7.19%0.55%0.19%0.14%
Net Income (Continuing)-4.2M-2.84M-1.56M-2.43M-1.08M-3.87M-31.69M-14.41M-11.7M-10.04M
Discontinued Operations000000-26.67M000
Minority Interest0000000000
EPS (Diluted)+-0.07-0.05-0.02-0.04-0.02-0.05-0.42-0.14-0.12-0.10
EPS Growth %-0.34%0.37%0.46%-0.46%0.45%-1.3%-8.13%0.67%0.14%0.17%
EPS (Basic)-0.07-0.05-0.02-0.04-0.02-0.05-0.42-0.14-0.12-0.10
Diluted Shares Outstanding58.21M62.13M63.09M67.3M76.86M84.02M92.09M99.44M100.5M102.98M
Basic Shares Outstanding58.21M62.13M63.09M67.3M76.86M84.02M92.09M99.44M97.53M102.98M
Dividend Payout Ratio----------

Balance Sheet

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Current Assets+515.63K1.11M172.15K1.47M1.07M3.39M25.54M17.95M4.61M4.37M
Cash & Short-Term Investments432.46K997.25K96.74K1.22M805.95K3.09M21.32M10.36M2.6M121.48K
Cash Only169.6K383.97K96.74K1.22M805.95K3.09M21.16M10.36M384.91K121.48K
Short-Term Investments262.86K613.28K0000159.84K02.21M0
Accounts Receivable53.88K00217.14K77.54K119.35K2.88M6.46K619.93K1.2M
Days Sales Outstanding-----18.5K3.1K32.357.59K503.16
Inventory000000531.92K2.96M1.05M887.51K
Days Inventory Outstanding------515.281.27K1.16K476.38
Other Current Assets000000809.08K3.55M343.82K1.88M
Total Non-Current Assets+21.03M21.69M22.05M24.08M25.16M26.86M10.41M15.34M12.06M14.03M
Property, Plant & Equipment21.03M21.69M22.05M24.08M25.16M26.86M4.82M15.34M5.74M12.73M
Fixed Asset Turnover-----0.00x0.07x0.00x0.01x0.07x
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments0000000000
Other Non-Current Assets000-24.08M005.59M06.32M1.29M
Total Assets+21.54M22.8M22.22M25.54M26.24M30.25M35.95M33.29M16.67M18.4M
Asset Turnover-----0.00x0.01x0.00x0.00x0.05x
Asset Growth %0.05%0.06%-0.03%0.15%0.03%0.15%0.19%-0.07%-0.5%0.1%
Total Current Liabilities+91.04K83.3K152.03K646.64K527.58K2.51M1.84M2.42M1.34M3.48M
Accounts Payable66.04K58.3K127.03K621.64K390.9K348.1K834.83K911.48K399.6K2.01M
Days Payables Outstanding2.12K2.19K7.64K42.84K8.16K648.16808.72389.87440.531.08K
Short-Term Debt000000879.32K998.08K479.64K346.75K
Deferred Revenue (Current)0000000000
Other Current Liabilities0000111.68K2.01M127.87K1463.55K0
Current Ratio5.66x13.28x1.13x2.27x2.04x1.35x13.87x7.42x3.44x1.25x
Quick Ratio5.66x13.28x1.13x2.27x2.04x1.35x13.58x6.19x2.65x1.00x
Cash Conversion Cycle------2.8K910.28.31K-97.69
Total Non-Current Liabilities+00000281.87K903.6K484.86K437.63K161.74K
Long-Term Debt000000797.66K0191.28K0
Capital Lease Obligations00000281.87K387.5K484.86K246.36K161.74K
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities000000-281.56K000
Total Liabilities91.04K83.3K152.03K646.64K527.58K2.79M2.75M2.9M1.78M3.65M
Total Debt+00000404.32K2.06M1.61M917.27K680.47K
Net Debt-169.6K-383.97K-96.74K-1.22M-805.95K-2.69M-19.09M-8.75M532.36K558.99K
Debt / Equity-----0.01x0.06x0.05x0.06x0.05x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage------423.20x-196.98x-121.48x-111.56x-105.13x
Total Equity+21.45M22.71M22.07M24.9M25.71M27.46M33.21M30.38M14.89M14.75M
Equity Growth %0.05%0.06%-0.03%0.13%0.03%0.07%0.21%-0.08%-0.51%-0.01%
Book Value per Share0.370.370.350.370.330.330.360.310.150.14
Total Shareholders' Equity21.45M22.71M22.07M24.9M25.71M27.46M33.21M30.38M14.89M14.75M
Common Stock31.18M33.77M34.18M38.31M40.21M43.8M68.33M85.75M63.56M89.48M
Retained Earnings-15.58M-18.2M-18.01M-16.31M-16.9M-20.49M-41.7M-66.2M-56.56M-83.85M
Treasury Stock0000000000
Accumulated OCI5.23M6.23M4.94M1.75M006.58M10.83M7.89M0
Minority Interest0000000000

Cash Flow

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operations+-1.68M-1.71M-999.86K-1.18M-1.36M-1.79M-7.99M-12.96M-5.94M-6.28M
Operating CF Margin %------762.07%-23.52%-177.84%-199.35%-7.2%
Operating CF Growth %-0.35%-0.02%0.42%-0.18%-0.15%-0.32%-3.45%-0.62%0.54%-0.06%
Net Income-4.2M-2.84M-1.56M-2.43M-1.54M-3.87M-12.02M-14.41M-8.64M-10.04M
Depreciation & Amortization11.38K9.71K6.07K5.3K24.88K126.8K614.71K539.69K453.04K600.32K
Stock-Based Compensation2.47M1.15M462.96K888.06K293.57K2.02M4.73M3.2M01.53M
Deferred Taxes-2.47M-1.15M0-1.26M000-808.08K00
Other Non-Cash Items2.47M1.15M-5.46K1.24M-39.57K-109.8K48.12K917.7K1.57M150.99K
Working Capital Changes37.99K-31.69K101.1K375.44K-94.39K38.55K-1.36M-2.4M675.37K1.48M
Change in Receivables45.04K-92626.86K-189.19K139.6K-41.81K-536.82K-12.84K201.14K-906.22K
Change in Inventory000000-665.57K-2.18M-51.86K397.48K
Change in Payables0067.15K000831.48K000
Cash from Investing+-949.71K-955.58K256.73K-1.74M-1.24M-1.23M-7.25M-2.31M1.39M358.65K
Capital Expenditures-1.05M-873.7K-433.8K-3.44K-103.21K-254.28K-3.99M-2.27M-436.98K-1.4K
CapEx % of Revenue-----107.98%11.73%31.2%14.66%0%
Acquisitions----------
Investments----------
Other Investing129.53K268.54K77.24K-1.74M-1.13M-978.96K-3.27M-33.64K1.82M360.05K
Cash from Financing+2.67M2.88M455.9K4.05M2.18M5.31M38.82M-1.05M-491.25K2.52M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing556.13K-67.68K-9.07K-259.04K-84.02K3.34M3.6M46K-95.42K16.01K
Net Change in Cash----------
Free Cash Flow+-2.74M-2.58M-1.43M-1.19M-1.46M-2.05M-11.97M-15.23M-6.18M-6.28M
FCF Margin %------870.05%-35.25%-209.04%-207.27%-7.2%
FCF Growth %0.06%0.06%0.45%0.17%-0.23%-0.4%-4.84%-0.27%0.59%-0.02%
FCF per Share-0.05-0.04-0.02-0.02-0.02-0.02-0.13-0.15-0.06-0.06
FCF Conversion (FCF/Net Income)0.40x0.60x0.64x0.49x1.25x0.46x0.25x0.90x0.51x0.63x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-20.05%-12.86%-6.99%-10.34%-4.28%-14.55%-104.48%-45.33%-51.7%-67.74%
Return on Invested Capital (ROIC)-15.16%-9.79%-5.55%-8.11%-3.64%-13.02%-48.46%-61.48%-48.48%-46.86%
Gross Margin------8223.91%-10.93%-1071.28%-1010.41%22.06%
Net Margin------164273.89%-9330.95%-19784.87%-39254.06%-1150.68%
Debt / Equity-----0.01x0.06x0.05x0.06x0.05x
Interest Coverage------423.20x-196.98x-121.48x-111.56x-105.13x
FCF Conversion0.40x0.60x0.64x0.49x1.25x0.46x0.25x0.90x0.51x0.63x
Revenue Growth------14323.18%-78.55%-59.07%2826.26%

Frequently Asked Questions

Growth & Financials

Zentek Ltd. (ZTEK) reported $0.9M in revenue for fiscal year 2024.

Zentek Ltd. (ZTEK) grew revenue by 2826.3% over the past year. This is strong growth.

Zentek Ltd. (ZTEK) reported a net loss of $8.2M for fiscal year 2024.

Dividend & Returns

Zentek Ltd. (ZTEK) has a return on equity (ROE) of -67.7%. Negative ROE indicates the company is unprofitable.

Zentek Ltd. (ZTEK) had negative free cash flow of $5.8M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.